Based on the possibility that TRIAD1 contributes to terminating the innate immune response via RTK degradation, we tested the impact of inhibiting TRIAD1-RTK substrates on AML progression and postchemotherapy relapse in this molecular subtype. Here, ARIH2 is linked to acute myeloid leukemia.